PIRS logo

Pieris Pharmaceuticals, Inc. Stock Price

NasdaqCM:PIRS Community·US$18.0m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

PIRS Share Price Performance

US$13.60
-3.20 (-19.05%)
US$13.60
-3.20 (-19.05%)
Price US$13.60

PIRS Community Narratives

There are no narratives available yet.

Snowflake Analysis

Adequate balance sheet slight.

4 Risks
1 Reward

Pieris Pharmaceuticals, Inc. Key Details

US$1.4m

Revenue

US$6.0m

Cost of Revenue

-US$4.6m

Gross Profit

US$11.3m

Other Expenses

-US$16.0m

Earnings

Last Reported Earnings
Sep 30, 2024
Next Reporting Earnings
n/a
-12.08
-342.09%
-1,179.96%
0%
View Full Analysis

About PIRS

Founded
2001
Employees
48
CEO
Stephen Yoder
WebsiteView website
www.pieris.com

Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.

Recent PIRS News & Updates

Recent updates

No updates